GH Research (NASDAQ:GHRS) Trading Up 3.8% – Time to Buy?

GH Research PLC (NASDAQ:GHRS)’s share price shot up 3.8% during trading on Wednesday . The stock traded as high as $9.60 and last traded at $9.50. 9,127 shares traded hands during trading, a decline of 88% from the average session volume of 79,000 shares. The stock had previously closed at $9.15.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on GHRS shares. HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of GH Research in a research note on Thursday, September 5th. JMP Securities reissued a “market outperform” rating and set a $39.00 target price on shares of GH Research in a research note on Wednesday, September 4th.

GH Research Trading Down 2.9 %

The stock’s 50 day moving average is $7.75 and its two-hundred day moving average is $10.38. The stock has a market capitalization of $466.71 million, a price-to-earnings ratio of -13.39 and a beta of 0.74.

GH Research (NASDAQ:GHRS) last posted its quarterly earnings data on Tuesday, September 3rd. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. On average, research analysts anticipate that GH Research PLC will post -0.85 earnings per share for the current year.

Institutional Trading of GH Research

A hedge fund recently raised its stake in GH Research stock. Lynx1 Capital Management LP grew its holdings in shares of GH Research PLC (NASDAQ:GHRS) by 80.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,310,563 shares of the company’s stock after buying an additional 1,471,946 shares during the quarter. GH Research makes up 9.1% of Lynx1 Capital Management LP’s portfolio, making the stock its 6th largest position. Lynx1 Capital Management LP owned about 6.36% of GH Research worth $35,291,000 as of its most recent SEC filing. 56.90% of the stock is currently owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).